{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:18:12Z","timestamp":1782184692720,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clgc.2018.08.006","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:09:58Z","timestamp":1536192598000},"page":"e38-e43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Aline","family":"Guillot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Meriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Negrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Pouessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Houede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tartas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-112X","authenticated-orcid":false,"given":"Mathieu","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Tinquaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Espenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Bouleftour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.08.006_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib2","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.08.006_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.08.006_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2018.08.006_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.08.006_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2018.08.006_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1749-6632.2012.06674.x","article-title":"The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction","volume":"1263","author":"Goessl","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.clgc.2018.08.006_bib10","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.08.006_bib12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.08.006_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.08.006_bib15","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","article-title":"American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition","volume":"67","author":"Colella","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2018.08.006_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clgc.2018.08.006_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clgc.2018.08.006_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2018.08.006_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2018.08.006_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2018.08.006_bib21","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2018.08.006_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2018.08.006_bib23","first-page":"1793","article-title":"Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease","volume":"33","author":"Sivolella","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2018.08.006_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.clgc.2018.08.006_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"Keizman","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.08.006_bib26","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.08.006_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib28","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/bjc.2013.516","article-title":"Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma","volume":"109","author":"Gilabert","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2018.08.006_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2018.08.006_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.08.006_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","volume":"73","author":"Loyson","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.clgc.2018.08.006_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.08.006_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac Surg Clin N Am"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:23Z","timestamp":1761564683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318303756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1558767318303756"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.08.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}